---
id: hyperbaric-oxygen-therapy_182
category: antimicrobials
tags: [hyperbaric-oxygen, hbot, clostridial-myonecrosis, necrotizing-fasciitis, co-poisoning]
deck: Infectious Diseases
created: 2025-11-11
modified: 2025-11-11
---

## Hyperbaric Oxygen Therapy (HBOT)

**Q:** What are the mechanisms, infectious disease indications (clostridial myonecrosis, necrotizing fasciitis), and evidence for hyperbaric oxygen therapy?

**A:**

## MECHANISM OF ACTION

**Mnemonic: "HIGH-O2-PRESSURE-EFFECTS"**

**Hyperbaric Oxygen = breathing 100% O2 at >1 atmosphere absolute (ATA) pressure (typically 2-3 ATA)**

### **Physiologic Effects:**

**1. Increased Dissolved O2 in Plasma:**
- **Normal (sea level, room air):** Dissolved O2 = 0.3 mL/dL
- **HBOT (100% O2 at 3 ATA):** Dissolved O2 = **6 mL/dL** (20x increase)
- **Effect:** Tissue oxygenation **independent of hemoglobin** (critical in ischemic/hypoxic tissues)

**2. Vasoconstriction with Maintained O2 Delivery:**
- **Reduces edema** (in compartment syndromes, crush injuries)

**3. Direct Antimicrobial Effects:**
- **Anaerobes:** **Toxic to obligate anaerobes** (Clostridium species - reactive oxygen species kill bacteria)
- **Aerobic bacteria:** Enhances oxidative killing by neutrophils

**4. Enhanced Neutrophil Function:**
- **Oxidative burst** (requires O2 - enhanced in hyperoxic environment)
- **Bacterial killing** improved

**5. Inhibition of Toxin Production:**
- ***Clostridium perfringens* alpha toxin** (lecithinase) production reduced

**6. Angiogenesis & Wound Healing:**
- **Promotes neovascularization** (long-term effect)

**Key Point:** **Increases dissolved O2 20x** → tissue oxygenation independent of hemoglobin | **Toxic to anaerobes**

---

## INFECTIOUS DISEASE INDICATIONS

**Mnemonic: "CLOSTRIDIAL-NECROTIZING-REFRACTORY-OSTEOMYELITIS"**

### **UHMS-Approved ID Indications (Undersea & Hyperbaric Medical Society):**

**1. Clostridial Myonecrosis (Gas Gangrene) - STRONG:**
**2. Necrotizing Soft Tissue Infections - MODERATE:**
**3. Refractory Osteomyelitis - MODERATE:**
**4. Intracranial Abscess - CONTROVERSIAL:**

---

## 1. CLOSTRIDIAL MYONECROSIS (GAS GANGRENE)

**Mnemonic: "SURGERY-ANTIBIOTICS-HBOT-TRIAD"**

### **Evidence: STRONGEST Indication**

***Clostridium perfringens* (90%) OR *C. septicum*, *C. novyi*:**

**Mechanism of HBOT Benefit:**
- **Inhibits alpha toxin production** (lecithinase - causes myonecrosis)
- **Direct bactericidal** (obligate anaerobes - O2 toxic)
- **Improves neutrophil killing** (oxidative burst)
- **Reduces tissue edema** (vasoconstriction)

**Evidence:**
- **Retrospective studies:** **Reduced mortality** (from 50% → 10-20%) when HBOT added to surgery + antibiotics
- **No RCTs** (unethical to withhold HBOT given historical mortality benefit)

### **HBOT Regimen:**

**Treatment:**
- **Emergent first session** (as soon as diagnosis made)
- **Protocol:** 100% O2 at **3 ATA x 90 minutes** (initial session)
- **Frequency:** **Q8-12H x 3-5 treatments** (first 24-48 hours) → **daily x 5-10 days** (total)
- **Adjunct to:** **Surgical debridement** (MANDATORY) + **antibiotics** (PCN + clindamycin)

**Key Point:** **Gas gangrene = STRONGEST HBOT indication** | **Adjunct to surgery + antibiotics** (NOT replacement)

---

## 2. NECROTIZING SOFT TISSUE INFECTIONS (NSTI)

**Mnemonic: "NECROTIZING-FASCIITIS-FOURNIER"**

### **Evidence: MODERATE**

**Includes:**
- **Necrotizing fasciitis** (Type I polymicrobial, Type II GAS)
- **Fournier gangrene** (necrotizing perineal infection)

**Mechanism of HBOT Benefit:**
- **Improves tissue oxygenation** (hypoxic/ischemic necrotic tissue)
- **Enhances neutrophil function** (oxidative killing)
- **Inhibits toxin production** (*Streptococcus pyogenes* exotoxins)
- **Reduces systemic toxicity**

**Evidence:**
- **Retrospective studies:** **Reduced mortality** (from 30-40% → 15-20%) with HBOT + surgery + antibiotics
- **Meta-analysis (2018):** **Reduced mortality** (OR 0.35, 95% CI 0.15-0.82)
- **Quality:** Observational studies (no RCTs)

### **HBOT Regimen:**

**Treatment:**
- **Protocol:** 100% O2 at **2.5-3 ATA x 90 minutes**
- **Frequency:** **BID x 2-3 days** → **daily x 5-10 days** (total)
- **Adjunct to:** **Surgical debridement** (MANDATORY) + **broad-spectrum antibiotics**

**Key Point:** **Necrotizing fasciitis = MODERATE evidence** (observational studies show mortality benefit)

---

## 3. REFRACTORY OSTEOMYELITIS

**Mnemonic: "CHRONIC-REFRACTORY-ADJUNCT"**

### **Evidence: MODERATE**

**Indication:**
- **Chronic refractory osteomyelitis** (failed antibiotics + debridement)

**Mechanism of HBOT Benefit:**
- **Enhances osteoblast function** (bone healing)
- **Angiogenesis** (neovascularization in ischemic bone)
- **Improves antibiotic penetration** (to poorly vascularized bone)
- **Enhances neutrophil function**

**Evidence:**
- **Prospective studies:** **Improved cure rates** (50-70% with HBOT vs 30-50% without)
- **Best evidence:** Diabetic foot osteomyelitis, post-traumatic osteomyelitis

### **HBOT Regimen:**

**Treatment:**
- **Protocol:** 100% O2 at **2.5 ATA x 90 minutes**
- **Frequency:** **Daily x 30-60 treatments** (prolonged course)
- **Adjunct to:** **Surgical debridement** + **prolonged antibiotics** (6-12 weeks)

**Key Point:** **Chronic refractory osteomyelitis = adjunct** (after failed standard therapy)

---

## 4. INTRACRANIAL ABSCESS

**Evidence: CONTROVERSIAL / WEAK**

**Mechanism:**
- **Theoretically improves O2 delivery to ischemic abscess cavity**
- **Enhances antibiotic penetration**

**Evidence:**
- **Case reports/series ONLY** (no controlled trials)
- **NOT routinely recommended** (IDSA guidelines do NOT recommend)

**Key Point:** **Intracranial abscess = NOT routinely recommended** (insufficient evidence)

---

## NON-INFECTIOUS UHMS-APPROVED INDICATIONS

**Mnemonic: "CO-DECOMPRESSION-CRUSH-RADIATION-WOUND"**

**Strong Evidence:**
1. **Carbon monoxide poisoning**
2. **Decompression sickness** (diving injury)
3. **Gas embolism** (air embolism)

**Moderate Evidence:**
4. **Crush injury / compartment syndrome** (acute traumatic ischemia)
5. **Delayed radiation injury** (soft tissue/bone radionecrosis)
6. **Compromised skin grafts/flaps**
7. **Thermal burns** (>20% BSA)

**Key Point:** **CO poisoning = most common non-infectious indication** (strong evidence)

---

## CONTRAINDICATIONS

**Mnemonic: "PNEUMOTHORAX-CHEMO-CLAUSTROPHOBIA"**

### **Absolute:**
1. **Untreated pneumothorax** (risk of tension pneumothorax during decompression)

### **Relative:**
1. **Claustrophobia** (chamber confinement)
2. **Upper respiratory infection** (Eustachian tube dysfunction → barotrauma)
3. **Seizure disorder** (O2 toxicity risk)
4. **Bleomycin** (increased pulmonary toxicity)
5. **Doxorubicin** (increased cardiotoxicity)
6. **Cisplatin** (increased ototoxicity)
7. **Disulfiram** (blocks superoxide dismutase → O2 toxicity)

**Key Point:** **Untreated pneumothorax = absolute contraindication**

---

## ADVERSE EFFECTS

**Mnemonic: "BAROTRAUMA-O2-TOXICITY-CLAUSTROPHOBIA"**

### **Common:**
1. **Barotrauma** (middle ear, sinuses - 10-20%)
   - **Equalization difficulty** → ear pain, TM rupture
2. **Claustrophobia** (5-10%)
3. **Fatigue** (after treatment)

### **Uncommon but Serious:**
1. **CNS O2 Toxicity (Seizures):**
   - **Incidence:** 1-2 per 10,000 treatments
   - **Risk factors:** Prolonged exposure (>90 minutes), high pressure (>3 ATA)
2. **Pulmonary O2 Toxicity:**
   - **Incidence:** Rare (with standard protocols)
   - **Symptoms:** Cough, chest pain, dyspnea
3. **Myopia (Reversible):**
   - **Mechanism:** Lens changes (reversible within weeks)

**Key Point:** **Barotrauma = most common** (10-20%) | **Seizures = rare** (1-2 per 10,000)

---

## CLINICAL USE SUMMARY

**When to Consider HBOT:**

**STRONG Indications (Adjunct to Surgery + Antibiotics):**
1. **Clostridial myonecrosis** (gas gangrene)
2. **Necrotizing soft tissue infections** (necrotizing fasciitis, Fournier gangrene)

**MODERATE Indications:**
3. **Chronic refractory osteomyelitis** (after failed standard therapy)

**NOT Recommended:**
- **Routine cellulitis, abscesses** (no benefit)
- **Intracranial abscess** (insufficient evidence)

**Key Point:** **HBOT = adjunct** (NOT replacement for surgery + antibiotics)

---

**Clinical Pearls:**
- **Increases dissolved O2 20x** → tissue oxygenation independent of hemoglobin
- **Gas gangrene = STRONGEST indication** (reduces mortality 50% → 10-20%)
- **Necrotizing fasciitis = MODERATE evidence** (observational studies show benefit)
- **HBOT = adjunct to surgery + antibiotics** (NOT replacement)
- **Clostridial myonecrosis: Emergent HBOT** (3 ATA x 90 min Q8-12H initially)
- **Chronic refractory osteomyelitis: 30-60 treatments** (prolonged course)
- **Untreated pneumothorax = absolute contraindication**
- **Barotrauma = most common adverse effect** (10-20%)
- **NOT routinely recommended:** Cellulitis, intracranial abscess

**Media:**

**Additional Resources:**
- **UHMS:** Hyperbaric indications (www.uhms.org)
- **Cochrane Review:** HBOT for necrotizing infections
- **IDSA Guidelines:** Gas gangrene management

**Sources:** [UHMS Guidelines], [Cochrane HBOT Review], [IDSA Gas Gangrene]
